- Home
- PCB vs OCGN Comparison
PCB vs OCGN Comparison
Compare PCB & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCB
- OCGN
- Stock Information
- Founded
- PCB 2003
- OCGN 2013
- Country
- PCB United States
- OCGN United States
- Employees
- PCB N/A
- OCGN N/A
- Industry
- PCB Major Banks
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCB Finance
- OCGN Health Care
- Exchange
- PCB Nasdaq
- OCGN Nasdaq
- Market Cap
- PCB 308.3M
- OCGN 246.8M
- IPO Year
- PCB N/A
- OCGN N/A
- Fundamental
- Price
- PCB $20.29
- OCGN $0.77
- Analyst Decision
- PCB Hold
- OCGN Strong Buy
- Analyst Count
- PCB 2
- OCGN 3
- Target Price
- PCB $22.00
- OCGN $5.67
- AVG Volume (30 Days)
- PCB 27.3K
- OCGN 3.9M
- Earning Date
- PCB 01-23-2025
- OCGN 11-08-2024
- Dividend Yield
- PCB 3.47%
- OCGN N/A
- EPS Growth
- PCB N/A
- OCGN N/A
- EPS
- PCB 1.68
- OCGN N/A
- Revenue
- PCB $94,833,000.00
- OCGN $4,700,000.00
- Revenue This Year
- PCB N/A
- OCGN N/A
- Revenue Next Year
- PCB $10.34
- OCGN N/A
- P/E Ratio
- PCB $12.35
- OCGN N/A
- Revenue Growth
- PCB N/A
- OCGN N/A
- 52 Week Low
- PCB $14.50
- OCGN $0.37
- 52 Week High
- PCB $22.20
- OCGN $2.11
- Technical
- Relative Strength Index (RSI)
- PCB 39.88
- OCGN 36.72
- Support Level
- PCB $21.17
- OCGN $0.81
- Resistance Level
- PCB $21.77
- OCGN $0.89
- Average True Range (ATR)
- PCB 0.54
- OCGN 0.05
- MACD
- PCB -0.18
- OCGN -0.01
- Stochastic Oscillator
- PCB 9.05
- OCGN 4.35
About PCB PCB Bancorp
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").